Carna Biosciences, Inc. (4572) Cash flow
Market cap
¥7.4B
P/E ratio
-3.5x
Karna Bioscience develops kinase inhibitor drugs and provides drug discovery support services to pharmaceutical companies and research institutions.
| 2014/12 | 2015/12 | 2016/12 | 2017/12 | 2018/12 | 2019/12 | 2020/12 | 2021/12 | 2022/12 | 2023/12 | 2024/12 | 2025/12 | |
| Depreciation & amortization | 31 | 19 | 22 | 12 | 13 | 9 | 12 | 19 | 34 | 36 | 31 | - |
| Cash from operations | -469 | 402 | -453 | -561 | -1,128 | 1,478 | -1,261 | -1,537 | -708 | -1,677 | -1,375 | -2,159 |
| Capital expenditures | -41 | -3 | -31 | -38 | -58 | -42 | -65 | -42 | -126 | -12 | -13 | -9 |
| Cash from investing | -42 | -3 | 248 | -38 | -58 | -41 | -70 | -42 | -126 | -11 | -13 | -25 |
| Proceeds from issuance of term debt, net | 100 | 100 | 400 | 100 | 350 | 300 | - | 300 | - | - | - | - |
| Repayments of term debt | -80 | -47 | -116 | -146 | -260 | -230 | -271 | -162 | -211 | -120 | -120 | -20 |
| Cash from financing | 67 | 603 | 755 | 296 | 688 | 2,122 | 724 | 1,065 | 367 | 1,182 | 567 | 605 |